Effects of AGEs, sRAGE and HMGB1 on clinical outcomes in multiple myeloma

Basit Öğe Kaydı
dc.authorid0000-0001-9556-8915en_US
dc.authorid0000-0002-2907-5108en_US
dc.authorid0000-0001-6349-9839en_US
dc.authorid0000-0001-7083-9379en_US
dc.authorid0000-0002-4303-9488en_US
dc.authorid0000-0002-8513-8476en_US
dc.contributor.authorGedük, Ayfer
dc.contributor.authorÖztaş, Berrin
dc.contributor.authorEryılmaz, Baldan Huri
dc.contributor.authorDemirsoy, Esra Terzi
dc.contributor.authorMengüç, Meral Uluköylü
dc.contributor.authorÜnal, Serkan
dc.date.accessioned2023-08-28T10:17:56Z
dc.date.available2023-08-28T10:17:56Z
dc.date.issued2023en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionThis study was supported by Kocaeli University Scientific Research Projects Coordination Unit. Project Number: 2559.en_US
dc.description.abstractPurpose The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of serum advanced glycation end products (AGEs), soluble RAGE (sRAGE) and high mobility group box 1 (HMGB1), in multiple myeloma (MM). Methods AGEs, sRAGE and HMGB1 concentrations of 54 newly diagnosed MM patients and 30 healthy volunteers were measured by ELISA. The estimations were done only once at diagnosis. The medical records of the patients were evaluated. Results There was no significant difference between the AGEs and sRAGE levels between the patient and control groups (p = 0.273, p = 0.313). In ROC analysis, a HMGB1 cutoff value of > 9170 pg/ml accurately discriminated MM patients (AUC = 0.672, 95% CI 0.561-0.77, p = 0.0034). AGEs level was found to be significantly higher in early-stage disease and HMGB1 in advanced disease (p = 0.022, p = 0.026). High HMGB1 levels were detected in patients whose with better first-line treatment response (p = 0.019). At 36 months, 54% of patients with low AGE were alive, compared to 79% of patients with high AGE (p = 0.055). Patients with high HMGB1 levels tended to have a longer PFS (median 43 mo [95% CI; 20.68-65.31] ) compared to patients with low HMGB1 levels (median 25 mo [95% CI; 12.39-37.6], p = 0.054). Conclusion In this study, a significant elevation of serum HMGB1 level was found in MM patients. In addition, the positive effects of RAGE ligands on treatment response and prognosis were determined.en_US
dc.description.sponsorshipKocaeli University Scientific Research Projects Coordination Unit [2559]en_US
dc.identifier.citationGeduk¹, A., Oztas, B., Eryılmaz, B. H., Demirsoy, E. T., Menguc, M. U., Unal, S., ... & Hacihanefioglu¹, A. (2023). Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma. Indian Journal of Hematology and Blood Transfusion, 39(2), 220-227.en_US
dc.identifier.doi10.1007/s12288-022-01574-6
dc.identifier.endpage227en_US
dc.identifier.issn0971-4502
dc.identifier.issn0974-0449
dc.identifier.issue2en_US
dc.identifier.pmid37006982en_US
dc.identifier.scopus2-s2.0-85140001487en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage220en_US
dc.identifier.urihttp://dx.doi.org/10.1007/s12288-022-01574-6
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11600
dc.identifier.volume39en_US
dc.identifier.wosWOS:000869327700002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorMengüç, Meral Uluköylü
dc.language.isoenen_US
dc.publisherSpringer Indiaen_US
dc.relation.ispartofIndian Journal of Hematology and Blood Transfusionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAGEsen_US
dc.subjectsRAGEen_US
dc.subjectHMGB1en_US
dc.subjectGlycation End-Productsen_US
dc.subjectSoluble Receptoren_US
dc.subjectOxidative Stressen_US
dc.titleEffects of AGEs, sRAGE and HMGB1 on clinical outcomes in multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
ayfer-geduk.pdf
Boyut:
1.09 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu